General anesthetics are drugs that have the ability to bring about a reversible loss of consciousness. Anesthetists administer these drugs to induce or maintain general anaesthesia to facilitate surgery. Some of these drugs are also used in lower dosages for pain management.
General Anesthesia Drugs can be divided into two categories, Intravenous Anesthetics, accounting for 69.62% and Inhalational Anesthetics, accounting for 30.38%. Intravenous Anesthetics widely used drugs are- Propofol, Etomidate, Midazolam, Barbiturates (such as thiopental), and so on. Desflurane, Isoflurane and Sevoflurane are the most widely used Inhalational Anesthetics. Propofol hold the largest market share of General Anesthesia Drugs with 33.83% market share. Sevoflurane market share is over 21.17%, being the second largest market share of General Anesthesia Drugs.
Europe is the largest supplier and consumption market of General Anesthesia Drugs, with a production market share of nearly 38% and sales market share nearly 32%. The second place is USA, following Europe with the production market share of 20% and the sales market share over 28%. Asia is another important market of General Anesthesia Drugs, enjoying 24% production market share and 25% sales market share.
According to this study, over the next five years the General Anesthesia Drugs market will register a 3.9% CAGR in terms of revenue, the global market size will reach USD 8170 million by 2024, from USD 6500 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in General Anesthesia Drugs business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of General Anesthesia Drugs market by product type, application, key manufacturers and key regions and countries.
This study considers the General Anesthesia Drugs value and volume generated from the sales of the following segments-
Segmentation by product type- breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Propofol
Etomidate
Midazolam
Sevoflurane
Isoflurane
Others
Segmentation by application- breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Intravenous Anesthetics
Inhalational Anesthetics
This report also splits the market by region- Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report- Breakdown data in in Chapter 3.
Astrazeneca
Fresenius-Kabi
AbbVie
Baxter Healthcare
B.Braun
Maruishi
Piramal
Hikma Pharmaceuticals
Mylan
Nhwa
Hengrui
Lunan
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global General Anesthesia Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of General Anesthesia Drugs market by identifying its various subsegments.
Focuses on the key global General Anesthesia Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the General Anesthesia Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of General Anesthesia Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
